What is the catalog number for Soblidotin?

The catalog number for Soblidotin is HY-14672.

What sizes are available for Soblidotin?

Soblidotin is available in the following size(s): 1 mg, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does Soblidotin come in?

Soblidotin is available in 5 different pack sizes.

Is Soblidotin in stock?

Soblidotin is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Soblidotin?

Soblidotin is manufactured by QuantiMol.

What is the estimated delivery time for Soblidotin?

Estimated delivery time for Soblidotin is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Soblidotin?

The safety data sheet for Soblidotin is available here: http://file.medchemexpress.com/batch_PDF/HY-14672/Soblidotin-SDS-MedChemExpress.pdf.

Soblidotin

Soblidotin (Auristatin PE) is a novel synthetic Dolastatin 10 derivative and inhibitor of tubulin polymerization.

Product Specifications

CAS Number

149606-27-9

Product Name Alternative

Auristatin PE; TZT-1027

UNSPSC

12352005

Target

Microtubule/Tubulin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Auristatin-PE.html

Purity

99.29

Solubility

H2O : < 0.1 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](C(C)C)C(N([C@@H]([C@H](CC)C)[C@H](OC)CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(NCCC2=CC=CC=C2)=O)=O)C)=O)[C@H](C(C)C)N(C)C

Molecular Formula

C39H67N5O6

Molecular Weight

701.98

References & Citations

[1]Yamamoto N, et al. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks. Cancer Sci. 2009 Feb;100 (2) :316-21.|[2]Fanale D, et al. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? Anal Cell Pathol (Amst) . 2015;2015:690916.|[3]Watanabe K, et al. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models. Clin Cancer Res. 2010 Feb 15;16 (4) :1170-8.